Advanced research and development of rvsv-marv vaccine.

Active Definitive Contract Awarded Last action

Contract number
75A50119C00022
Awardee
Awarding agency
Obligated
$89,026,883

Award facts

Contract value 75% obligated
  • $89,026,882.76 Current, with exercised options
  • $118,929,507.76 Potential, with all options
Completion date 78% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Cambridge, MA 02142, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Exercise an Option P00026 · The purpose of this modification is to exercise option 6. $33,479,229
Other Administrative Action P00025 · The purpose of this modification is to correct the period of performance for CLIN0004/option 3 to april 30, 2026, to align with IPP. $0
Exercise an Option P00024 · The purpose of this modification is to exercise and fully fund option 4/CLIN00005 $19,456,973
Supplemental Agreement for work within scope P00023 · Advanced research and development of rvsv-marv vaccine. - update POP $0
Other Administrative Action P00022 · Advanced research and development of rvsv-marv vaccine. - admin MOD $0
Supplemental Agreement for work within scope P00021 · Advanced research and development of rvsv-marv vaccine. - supplemental funding MOD $7,490,707
Supplemental Agreement for work within scope P00020 $0
Supplemental Agreement for work within scope P00019 $0
Supplemental Agreement for work within scope P00018 $0
Supplemental Agreement for work within scope P00017 $0
Supplemental Agreement for work within scope P00016 $5,816,098
Other Administrative Action P00015 $0
Supplemental Agreement for work within scope P00014 $0
Other Administrative Action P00013 $0
Funding Only Action P00012 $230,096
Other Administrative Action P00011 $243,008
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Exercise an Option P00008 $12,294,690
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $10,016,082
Show all 27

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Public Health Vaccines LLC for advanced research and development of RVSV-MARV vaccine on February 1, 2019. The contract carries a ceiling value of $118.9 million and is priced on a cost-plus-fixed-fee basis with no set-aside applied.

Place of performance is Cambridge, MA. The award exercises option 6, with ultimate completion scheduled for January 31, 2029.

In fiscal year 2024, the contract reported $4.1 million invoiced against 10.0 FTEs and 20,944 contractor hours. The derived government-paid hourly rate was $197.14 per hour. Teaming depth shows five subcontractors reported, with 89 percent of contractor hours subcontracted out.

Quick answers

Who was awarded contract 75A50119C00022?

75A50119C00022 was awarded to Public Health Vaccines LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on February 1, 2019.

How much is contract 75A50119C00022 worth?

The government has obligated $89,026,883 on 75A50119C00022. Its potential value, with all options, is $118,929,508.

Was contract 75A50119C00022 competed?

The extent of competition for 75A50119C00022 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login